OncoImmunity Becomes the First Company to Obtain the CE-IVD Mark for Clinical Use of a Machine-Learning Based Neoantigen Prediction Technology
OSLO, Norway--(BUSINESS WIRE)--Mar 11, 2019--OncoImmunity has become the first company to obtain a CE-IVD mark for the clinical use of a machine-learning based neoantigen predictio…
